Information on glucocorticoid therapy in the main studies of biological agents

Joint Bone Spine

Volumn 78, Issue 5, 2011, Pages 478-483

  André, Vincent ^a   le Goff, Benoît ^a   Leux, Christophe ^a   Pot Vaucel, Marianne ^a   Maugars, Yves ^a   Berthelot, Jean Marie ^a  

^a HÔTEL DIEU   (France)

Author keywords

Abatacept; Adalimumab; Certolizumab; Etanercept; Glucocorticoids; Golimumab; Infliximab; Prednisone; Rituximab; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PREDNISONE; RITUXIMAB; TOCILIZUMAB;

ARTICLE; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG INFORMATION; HUMAN; OPTIMAL DRUG DOSE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS;

EID: 80053447613     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.01.001     Document Type: Article

References (28)

1. Wolfe F., Caplan L., Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and antitumor necrosis factor therapy. Arthritis Rheum 2006, 54:628-634.
2. Greenberg J.D., Reed G., Kremer J.M., et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010, 69:380-386.
3. Ruyssen-Witrand A., Fautrel B., Saraux A., et al. Infections induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2010, 77:246-251.
4. Machold K.P., Landewé R., Smolen J.S., et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis 2010, 69:495-502.
5. Hafström I., Albertsson K., Boonen A., et al. Remission achieved after 2years treatment with low-dose prednisone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4years: an open 2-year continuation study. Ann Rheum Dis 2009, 68:508-513.
6. Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007;24:CD006356.
7. Gorter S.L., Bijlsma J.W., Cutolo M., et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010, 69:1010-1014.
8. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2008, 58:S126-S135.
9. Seror R., Dougados M., Gossec L. Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol 2009, 27:807-813.
10. Tengstrand B., Larsson E., Klareskog L., et al. Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density. Scand J Rheumatol 2007, 36:351-358.
11. Pincus T., Swearingen C.J., Luta G., et al. Efficacy of prednisone 1-4mg/day in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled withdrawal clinical trial. Ann Rheum Dis 2009, 68:1715-1720.
12. Wiens A., Venson R., Correr C.J., et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010, 30:339-353.
13. Pereira R.M., Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine 2010, 10.1016/j.jbspin.2010.02.025.
14. Hoes J.N., Jacobs W.G., Verstappen S.M.M., et al. Adverse events of low to medium oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis 2009, 68:1833-1838.
15. Huscher D., Thiele K., Gromnica-Ihle E., et al. Dose related pattern of glucocorticoid-induced side-effects. Ann Rheum Dis 2009, 68:1119-1124.
16. Engvall I.L., Svensson B., Tengstrand B., et al. Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study. Arthritis Res Ther 2008, 10:R128.
17. Ibanez M., Ortiz A.M., Castrejon I., et al. A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass. Arthritis Res Ther 2010, 12:R50.
18. Ruyssen-Witrand A., Fautrel B., Saraux A., et al. Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2010, 77:246-251.
19. Smolen J.S., Aletaha D., Bijlsma J.W., et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637.
20. Todoerti M., Scirè C.A., Boffini N., et al. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann N Y Acad Sci 2010, 1193:139-145.
21. Hetland M.L., Christensen I.J., Tarp U., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, and infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010, 62:22-32.
22. Aletaha D., Landewé R., Karonitsch T., et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum Arthritis Care Res 2008, 59:1371-1377.
23. Conn D.L., Lim S.S. New role for an old friend: prednisone is a disease-modifying agent in early rheumatoid arthritis. Curr Opin Rheumatol 2003, 15:193-196.
24. Mouterde G., Dernis E., Ruyssen-Witrand A., et al. Indications of glucorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on date from the literature and expert opinion. Joint Bone Spine 2010, 77:597-603.
25. Brocq O., Millasseau E., Albert C., et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 2009, 76:350-355.
26. Thiele K., Buttgereit F., Huscher D., et al. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum 2005, 53:740-747.
27. Berthelot J.M., Benoist-Gérard S., le Goff B., et al. Outcome and safety of anti-TNF antagonist therapy in 475 consecutive outpatients (with rheumatoid arthritis or spondylarthropathies) treated by a single physician, according to their eligibility for clinical trials. Joint Bone Spine 2010, 77:564-569.
28. Pagnoux C., Dechartres A., Giraudeau B., et al. Reporting of corticosteroid use in systemic disease trials: evidence from a systematic review of the potential impact on treatment effect. Arthritis Care Res (Hoboken) 2010, 62:1002-1028.